Recurrent Nasopharyngeal Carcinoma
27
9
10
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
3.7%
1 terminated out of 27 trials
66.7%
-19.8% vs benchmark
22%
6 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (27)
PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients
Proton Therapy for Recurrent Nasopharyngeal Carcinoma
Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer
Watch-and-Wait After Immunochemotherapy in Locally Recurrent Nasopharyngeal Carcinoma
Adjuvant vs Surgery Only in Early-stage Recurrent NPC
Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC
Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma
Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma
Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure
Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.
A Transoral Retropterygoid Approach to Resect Recurrent Nasopharyngeal Carcinoma
Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC
Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma
Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma
Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT
A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma
Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer